ArticleThe Journal of experimental medicine2021

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses.

Ryo Shinnakasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.